Universal CAR-T Cell Therapy for MM

This study is a non-randomized, open-label, single-arm clinical trial designed to assess the efficacy and safety of combination therapy for r/r multiple myeloma using universal CAR-T cells targeting BCMA .

Inclusion criteria

• Expected survival of at least 3 months;
• Subjects should have measurable disease that meets the IMWG 2016 criteria;
• Previously received at least two lines of prior anti-myeloma therapy ；
• Relapse , failure to achieve at least a minimal response, or disease progression after the last treatment ；
• BCMA positive；
• ECOG score 0-1；
• No severe impairment or suppression of liver, kidney, coagulation, bone marrow, or lung function.

Exclusion criteria

• Pregnant or breastfeeding women;
• History of other malignant tumors;
• Active autoimmune diseases requiring immunotherapy;
• Previously received allogeneic stem cell transplantation;
• Previous use of CAR-T cells or other genetically modified T cell therapies;
• Previously received targeted BCMA therapy;
• Severe cardiovascular disease;
• Active infection;
• Positive virology test;
• Clinically significant central nervous system (CNS) diseases or pathological changes.